On May 26, JD Health fell 3.2% in regular trading, trading at HK$38.78/share, with trading volume of HK$144 million. The stock extended its multi-day selloff as newly implemented regulations on GLP-1 weight loss drug online sales continue to weigh on the company's digital pharmacy business.

Since May 15, new rules require patients to present a hospital-issued paper prescription to purchase GLP-1 weight loss drugs, effectively invalidating prescriptions issued by internet hospitals. Multiple pharmacies have already delisted related products from platforms including JD Health, directly suppressing online pharmaceutical sales. Additionally, the revised Drug Administration Law Implementation Regulations took effect the same day, intensifying market concerns over tightening oversight of online prescription drug sales.

Despite ongoing share buybacks — including a HK$29.45 million repurchase of 729,300 shares on May 22 — and major shareholder Liu Qiangdong increasing his stake by approximately 64 million shares to 70.04% on May 18, selling pressure persists. Within the Internet and Direct Marketing Retail sector, broad weakness prevails, with Ali Health down 2.34%, PA Good Doctor down 2.5%, Meituan down 4.67%, and JD down 2.63%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)